UCB is changing the way it conducts some of its research studies, removing the need for patients to attend hospitals by allowing them to take part in virtual clinical trials at home.
As part of pharmaphorum’s ‘eye-on-innovation’ series, Paul Tunnah speaks to UCB’s head of innovation, Gregory Miller, about how the company is creating a culture based around ‘design thinking’.
The FDA has rejected Amgen and UCB’s Evenity (romosozumab) osteoporosis drug after a late-stage trial unexpectedly highlighted a potential cardiac safety risk.
